论文部分内容阅读
目的研究肺腺癌中血管内皮生长因子D及其受体表达水平与病灶氟代脱氧葡萄糖(FDG)摄取程度的关系,探讨FDG摄取程度是否可作为肺腺癌中预测靶向治疗疗效的一项指标。方法使用寡DNA基因芯片技术(Genespring 7.3)对6例肺腺癌病例行基因水平分析,并使用免疫组化方法对基因分析进一步证实。使用抗VEGF-D抗体对49例肺腺癌病理石蜡包埋切片行免疫组化染色。所有患者常规行PET检查,感兴趣区的定量分析采用标准摄取值(SUV)。使用独立样本t检验,χ2检验及F检验行统计学分析,使用Kaplan-Meier方法计算无病生存曲线。结果 VEGF-D表达在低FDG摄取组中远远高于高FDG摄取组(=0.0241)。免疫组化研究进一步证实:VEGF-D阴性组的FDG摄取程度明显高于阳性组(<0.001)。VEGF-D高表达组中发生淋巴结转移(<0.001)及复发(<0.001)的病例数均明显低于VEGF-D低表达组。VEGF-D高表达的患者其无病生存率明显高于低表达者。结论 VEGF-D表达与肺腺癌患者FDG摄取程度呈负相关,且可能作为肺腺癌患者淋巴结转移,组织学分型及复发的预测指标。PPPP
Objective To investigate the relationship between the expression of vascular endothelial growth factor D and its receptor and the uptake of FDG in lung adenocarcinoma and to investigate whether FDG uptake can be used as a predictive therapeutic target in lung adenocarcinoma index. Methods Six cases of lung adenocarcinoma were genotyped by Genespring 7.3. The gene analysis was further confirmed by immunohistochemistry. 49 cases of lung adenocarcinoma pathological paraffin embedded sections were immunohistochemically stained with anti-VEGF-D antibody. PET was routinely performed in all patients. Quantitative analysis of the region of interest was based on the standard uptake (SUV). Independent sample t-test, χ2 test and F test were used for statistical analysis, and Kaplan-Meier method was used to calculate disease-free survival curves. Results VEGF-D expression was much higher in low FDG uptake group than in high FDG uptake group (= 0.0241). Immunohistochemical study further confirmed: FDG uptake in VEGF-D negative group was significantly higher than that in positive group (<0.001). The number of cases with lymph node metastasis (<0.001) and recurrence (<0.001) in VEGF-D overexpression group was significantly lower than that in VEGF-D low expression group. Patients with high expression of VEGF-D disease-free survival was significantly higher than those with low expression. Conclusion The expression of VEGF-D is negatively correlated with the extent of FDG uptake in patients with lung adenocarcinoma and may be used as a predictor of lymph node metastasis, histological type and recurrence in patients with lung adenocarcinoma. PPPP